General description

The H1047R substitution is a somatic mutation in p110α that has been associated with tumours of the colon, stomach, breast and brain. Combined in vitro and in vivo studies have shown that this mutation confers higher lipid kinase activity than wild type, and is able to induce oncogenic transformation. (Samuels Y. et al., Science, (2004); 304: 554; Kang S. et al., PNAS, (2005);102: 802-807 and Zhao J.J. et al., PNAS, (2005);102:18443-18448).

Complex of N-terminal 6His-tagged recombinant human p110α full length, containing the mutation H1047R, and untagged, recombinant, human p85α full length.

Legal Information

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

For Specific Activity data, refer to the Certificate of Analysis for individual lots of this enzyme.

Packaging

Also available in 250µg size --call for pricing and availability and reference catalog number 14-792M when ordering the 250µg size.

Physical form

50 mM Tris/HCl pH8.0, 300 mM NaCl, 0.1 mM EGTA, 0.03% Brij-35, 270 mM sucrose, 0.2 mM PMSF, 1 mM benzamidine, 0.1% 2-mercaptoethanol. Frozen solution.